|
The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma. |
|
|
|
Honoraria - Bionest Partner; Horizon CME; Research to Practice; Targeted Oncology |
Consulting or Advisory Role - Adaptimmune; ADRx; Apexigen; Ayala Pharmaceuticals; Bayer; Boehringer Ingelheim; Cytokinetics; Daiihi Sankyo; Deciphera; EcoR1 Capital; EcoR1 Capital; EMD Serono; Epizyme; GlaxoSmithKline; Immune Design; Intellisphere; Lilly; Novartis; Pfizer; PTC Therapeutics |
Speakers' Bureau - Adaptimmune; GlaxoSmithKline; Lilly; Novartis |
Research Funding - GlaxoSmithKline; Merck; Pfizer; TRACON Pharma |
Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker |
Expert Testimony - Health Advances |
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; GlaxoSmithKline; Lilly |
|
|
Consulting or Advisory Role - Deciphera; Foundation Medicine |
|
|
Leadership - Innate Pharma |
Honoraria - AstraZeneca; Bayer; BMS; Deciphera; Ignyta; MSD; PharmaMar; Roche |
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Deciphera; Deciphera; Deciphera; Karyopharm Therapeutics; Pharmamar; Roche |
Research Funding - AstraZeneca (Inst); Bayer (Inst); BMS (Inst); DEciphera (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); OSE Pharma (Inst); Pharmamar (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Roche |
|
|
No Relationships to Disclose |
|
|
Research Funding - Adaptimmune (Inst); GlaxoSmithKline (Inst); Immatics (Inst) |
|
Albiruni Ryan Abdul Razak |
Consulting or Advisory Role - Adaptimmune; Bayer; GlaxoSmithKline; Inhibrx; Medison |
Research Funding - 23 and Me; Abbvie; Adaptimmune; Amgen; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Deciphera; Frontier Therapeutics; GlaxoSmithKline; Iterion Therapeutics; Karyopharm Therapeutics; MedImmune; Merck; Neoleukin Therapeutics; Pfizer; Rain Therapeutics; Roche/Genentech; Symphogen |
Expert Testimony - Medison |
|
|
Honoraria - Bayer; Deciphera; PharmaMar |
|
|
Consulting or Advisory Role - Adaptimmune; Boehringer Ingelheim |
Research Funding - Adaptimmune (Inst); Amgen (Inst); Blueprint Medicines (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Rain Therapeutics (Inst); TRACON Pharma (Inst) |
|
|
Consulting or Advisory Role - AADi; Adaptimmune; Deciphera; Epizyme |
Research Funding - Adaptimmune (Inst); Athenex (Inst); Deciphera (Inst); Foghorn Therapeutics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Presage Biosciences (Inst) |
Travel, Accommodations, Expenses - Epizyme |
|
|
Research Funding - AB Science (Inst); Adaptimmune (Inst); Advenchen Laboratories (Inst); Ayala Pharmaceuticals (Inst); Bavarian Nordic (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); BTG (Inst); C4 Therapeutics (Inst); CBA Pharma (Inst); Deciphera (Inst); Desmoid Tumor Research Foundation; Epizyme (Inst); FORMA Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Gradalis (Inst); Incyte (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Monopar Therapeutics (Inst); Novartis (Inst); Noxopharm (Inst); Philogen (Inst); PTC Therapeutics (Inst); Rain Therapeutics (Inst); Salarius Pharmaceuticals (Inst); SpringWorks Therapeutics (Inst); Takeda (Inst); Theseus Pharmaceuticals (Inst); TRACON Pharma (Inst); TRACON Pharma (Inst); Trillium Therapeutics (Inst) |
|
|
Speakers' Bureau - Alexion Pharmaceuticals; Astellas Pharma; Gilead Sciences; GlaxoSmithKline; Novartis; Sanofi |
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; Gilead Sciences; Sanofi |
|
|
Consulting or Advisory Role - AADi; Adaptimmune; Decipher Biosciences |
Speakers' Bureau - AADi; Deciphera |
Travel, Accommodations, Expenses - AADi |
|
|
Consulting or Advisory Role - AADi; Apexigen; Bayer; Daichii Sankyo; Deciphera; Epizyme; GlaxoSmithKline; Obsidian Therapeutics; Sensei Biotherapeutics; T-Knife |
Speakers' Bureau - Deciphera |
Research Funding - Obsidian Therapeutics (Inst) |
|
|
|
|
|
|
Stock and Other Ownership Interests - Adaptimmune |
Travel, Accommodations, Expenses - Adaptimmune |
|
|
|
Stock and Other Ownership Interests - Adaptimmune |
|
|
|
|
Stock and Other Ownership Interests - Adaptimmune |
|
|
|
Stock and Other Ownership Interests - Adaptimmune |
|
|
|
Stock and Other Ownership Interests - Adaptimmune |
|
|
Honoraria - Adaptimmune; GlaxoSmithKline; Pfizer; Rain Therapeutics; SERVIER |
Consulting or Advisory Role - Adaptimmune; GlaxoSmithKline; Nektar; Pfizer; Rain Therapeutics; Rain Therapeutics; Servier |